{
    "clinical_study": {
        "@rank": "30199", 
        "arm_group": {
            "arm_group_label": "Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)", 
            "arm_group_type": "Experimental", 
            "description": "INDUCTION CHEMOTHERAPY: Patients receive cytarabine SC BID and omacetaxine mepesuccinate SC BID on days 1-14. Treatment for induction therapy repeats every 28 days for up to 4 courses or until patients achieve CR in the absence of disease progression or unacceptable toxicity.\nCONSOLIDATION THERAPY: Patients alternate courses between decitabine and OAG. Patients receive decitabine IV on days 1-5. Patients alternate with OAG courses, comprising cytarabine SC BID on days 1-7 and omacetaxine mepesuccinate SC BID on days 1-7. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies the side effects and how well omacetaxine mepesuccinate,\n      cytarabine, and decitabine works in treating older patients with newly diagnosed acute\n      myeloid leukemia. Omacetaxine mepesuccinate, cytarabine, and decitabine may stop the growth\n      of cancer cells by blocking some of the enzymes needed for cell growth."
        }, 
        "brief_title": "Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", 
        "condition": [
            "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", 
            "Adult Acute Megakaryoblastic Leukemia (M7)", 
            "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", 
            "Adult Acute Monoblastic Leukemia (M5a)", 
            "Adult Acute Monocytic Leukemia (M5b)", 
            "Adult Acute Myeloblastic Leukemia With Maturation (M2)", 
            "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", 
            "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", 
            "Adult Acute Myeloid Leukemia With Del(5q)", 
            "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", 
            "Adult Acute Myelomonocytic Leukemia (M4)", 
            "Adult Erythroleukemia (M6a)", 
            "Adult Pure Erythroid Leukemia (M6b)", 
            "Secondary Acute Myeloid Leukemia", 
            "Untreated Adult Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Leukemia", 
                "Leukemia, Erythroblastic, Acute", 
                "Leukemia, Megakaryoblastic, Acute", 
                "Leukemia, Monocytic, Acute", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelomonocytic, Acute", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Leukemia, Myelomonocytic, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To study the complete response rate following OAG (omacetaxine mepesuccinate, cytarabine)\n      in newly diagnosed acute myeloid leukemia patients unfit for intensive induction therapy.\n\n      II. To assess the toxicity of OAG using the Cancer Therapy Evaluation Program (CTEP)\n      National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE\n      version 4.0).\n\n      SECONDARY OBJECTIVES:\n\n      I. To study the disease-free and overall survival of OAG and decitabine in newly diagnosed\n      acute myeloid leukemia patients unfit for intensive induction therapy.\n\n      OUTLINE:\n\n      INDUCTION CHEMOTHERAPY: Patients receive cytarabine subcutaneously (SC) twice daily (BID)\n      and omacetaxine mepesuccinate SC BID on days 1-14. Treatment for induction therapy repeats\n      every 28 days for up to 4 courses or until patients achieve complete response (CR) in the\n      absence of disease progression or unacceptable toxicity.\n\n      CONSOLIDATION THERAPY: Patients alternate courses between decitabine and OAG. Patients\n      receive decitabine intravenously (IV) on days 1-5. Patients alternate with OAG courses,\n      comprising cytarabine SC BID on days 1-7 and omacetaxine mepesuccinate SC BID on days 1-7.\n      Treatment repeats every 28 days for up to 24 months in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up at 30 days, every 3 months for\n      1 year, every 6 months for 1 year, and then annually thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have an unequivocal histologic diagnosis of acute myeloid leukemia (AML) (including\n             secondary AML)\n\n          -  No prior therapy for AML except hydroxyurea to control counts\n\n          -  Must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of\n             birth control; abstinence) prior to study entry and for the duration of study\n             participation\n\n          -  Subject or legal representative must understand the investigational nature of this\n             study and sign an independent ethics committee/institutional review board approved\n             written informed consent form prior to receiving any study related procedure\n\n        Exclusion Criteria:\n\n          -  Subjects with the diagnosis of acute promyelocytic leukemia ([15;17])\n\n          -  Unwilling or unable to follow protocol requirements\n\n          -  Any condition which in the Investigator's opinion deems the subject an unsuitable\n             candidate to receive study drug\n\n          -  Received an investigational agent for another disease within 30 days prior to\n             enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029417", 
            "org_study_id": "I 245213", 
            "secondary_id": [
                "NCI-2013-02425", 
                "I 245213", 
                "P30CA016056"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)", 
                "description": "Given SC", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ARA-C", 
                    "arabinofuranosylcytosine", 
                    "arabinosylcytosine", 
                    "Cytosar-U", 
                    "cytosine arabinoside"
                ]
            }, 
            {
                "arm_group_label": "Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)", 
                "description": "Given SC", 
                "intervention_name": "omacetaxine mepesuccinate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CGX-635", 
                    "homoharringtonine"
                ]
            }, 
            {
                "arm_group_label": "Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)", 
                "description": "Given IV", 
                "intervention_name": "decitabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "5-aza-dCyd", 
                    "5AZA", 
                    "DAC"
                ]
            }, 
            {
                "arm_group_label": "Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Decitabine", 
                "Homoharringtonine", 
                "Harringtonines"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "contact": {
                "email": "ASKRPCI@roswellpark.org", 
                "last_name": "Roswell Park", 
                "phone": "877-275-7724"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14263"
                }, 
                "name": "Roswell Park Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Meir Wetzler", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age", 
        "overall_official": {
            "affiliation": "Roswell Park Cancer Institute", 
            "last_name": "Meir Wetzler", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Defined as recovery of morphologically normal bone marrow (< 5% blasts) and blood counts (absolute neutrophil count [ANC] >= 1x10^9/L, platelet counts >= 100x10^9/LO) and rare circulating leukemic blasts or evidence of extramedullary disease. Analyzed using exact binomial probabilities in a two-stage design.", 
                "measure": "Proportion of the evaluable population of interest who experience a complete response in the poor and good prognosis groups", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Tabulated by grade across.", 
                "measure": "Frequency of adverse events, graded according to NCI CTCAE v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after last dose of study drugs"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029417"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Roswell Park Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Roswell Park Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}